Payment overview · 2025
General Payments
$492.70
12 reported records · 4 companies
Healthcare provider profile · identity verified
Justin Gregory Miller, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WILMINGTON, NC · NPI 1760590632
Verified facts
What the public records show
CMS Open Payments records show Justin Gregory Miller, MD received $492.70 in general payments during 2025 across 12 reported records.
Boston Scientific Corporation accounted for 76.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $375.27 | 76.2% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.91 | 8.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.92 | 8.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.60 | 6.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $492.70 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EXALT Model D Normalized: exalt model d |
Device | Boston Scientific Corporation | $212.14 | 2 | 2025 |
Source payment records
|
|||||
| Acquire Normalized: acquire |
Device | Boston Scientific Corporation | $119.36 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.91 | 2 | 2025 |
Source payment records
|
|||||
| Axios Normalized: axios |
Device | Boston Scientific Corporation | $43.77 | 1 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1146 | 321 |
| Levothyroxine Sodium | Levothyroxine Sodium | 493 | 133 |
| Losartan Potassium | Losartan Potassium | 438 | 127 |
| Omeprazole | Omeprazole | 371 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 97 |
| Lisinopril | Lisinopril | 323 | 91 |
| Gabapentin | Gabapentin | 255 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 63 |
| Simvastatin | Simvastatin | 196 | 55 |
| Meloxicam | Meloxicam | 194 | 87 |
| Sertraline Hcl | Sertraline Hcl | 194 | 53 |
| Potassium Chloride | Potassium Chloride | 155 | 47 |
| Metformin Hcl Er | Metformin Hcl | 154 | 44 |
| Furosemide | Furosemide | 145 | 43 |
| Trazodone Hcl | Trazodone Hcl | 134 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 36 |
| Memantine Hcl | Memantine Hcl | 120 | 25 |
| Allopurinol | Allopurinol | 118 | 31 |
| Bupropion Xl | Bupropion Hcl | 116 | 33 |
| Ezetimibe | Ezetimibe | 113 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 49 |
| Metformin Hcl | Metformin Hcl | 105 | 34 |
| Donepezil Hcl | Donepezil Hcl | 99 | 26 |
| Tramadol Hcl | Tramadol Hcl | 96 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 27 |
| Eliquis | Apixaban | 89 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 24 |
| Carvedilol | Carvedilol | 79 | 24 |
| Ozempic | Semaglutide | 78 | 18 |
| Alprazolam | Alprazolam | 77 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 25 |
| Jardiance | Empagliflozin | 74 | 20 |
| Chlorthalidone | Chlorthalidone | 73 | 26 |
| Pregabalin | Pregabalin | 72 | 15 |
| Mirtazapine | Mirtazapine | 69 | 26 |
| Prednisone | Prednisone | 67 | 41 |
| Synthroid | Levothyroxine Sodium | 67 | 19 |
| Celecoxib | Celecoxib | 65 | 20 |
| Klor-Con M20 | Potassium Chloride | 65 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Finasteride | Finasteride | 63 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 17 |
| Famotidine | Famotidine | 54 | 17 |
| Alendronate Sodium | Alendronate Sodium | 52 | 16 |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Atenolol | Atenolol | 46 | 12 |
| Glimepiride | Glimepiride | 46 | 11 |
| Clonazepam | Clonazepam | 45 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 14 |
| Spironolactone | Spironolactone | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 37 |
| Lorazepam | Lorazepam | 41 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Valsartan | Valsartan | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 21 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 13 |
| Silodosin | Silodosin | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Topiramate | Topiramate | 19 | suppressed |
| Wegovy | Semaglutide | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 18 |
| Estradiol | Estradiol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $492.70 · 12 records | Boston Scientific Corporation | Acquire, Axios, EXALT Model D, OMVOH, VELSIPITY, XELJANZ, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error